DiscoverJNIS PodcastPoint/Counterpoint: Stenting for idiopathic intracranial hypertension
Point/Counterpoint: Stenting for idiopathic intracranial hypertension

Point/Counterpoint: Stenting for idiopathic intracranial hypertension

Update: 2023-08-16
Share

Description

In this podcast, JNIS Editor-in-Chief, Dr. Felipe C. Albuquerque, speaks with Dr. Michael Levitt (1) and Dr. Colin Derdeyn (2), authors of a pair of editorials discussing the practice of dural venous sinus stenting for patients with idiopathic intracranial hypertension.


 


Point: Dural venous sinus stenting should be considered a first-line treatment option for select patients with idiopathic intracranial hypertension https://jnis.bmj.com/content/early/2023/06/20/jnis-2023-020597 


Counterpoint: stenting for idiopathic intracranial hypertension should be trialed

https://jnis.bmj.com/content/early/2023/06/20/jnis-2023-020404 


 


These articles are free-to-access for a month following the publication of this podcast. 


 


Please subscribe to the JNIS Podcast via all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify, to get the latest episodes. Also, please consider leaving us a review or a comment on the JNIS Podcast iTunes page: https://podcasts.apple.com/gb/podcast/jnis-podcast/id942473767 


Thank you for listening! This episode was edited by Brian O'Toole. 


 


(1) Neurological Surgery, University of Washington School of Medicine, Seattle, Washington, USA

(2) Radiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Point/Counterpoint: Stenting for idiopathic intracranial hypertension

Point/Counterpoint: Stenting for idiopathic intracranial hypertension

BMJ Group